{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"30.2","upperLimit":"69.8","value":"50.0"},{"groupId":"OG002","lowerLimit":"31.1","upperLimit":"68.9","value":"50.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"Non-small cell lung cancer (NSCLC)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"25.9","upperLimit":"65.3","value":"45.0"},{"groupId":"OG002","lowerLimit":"23.3","upperLimit":"60.5","value":"40.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"20"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"22"}],"units":"Participants"}],"title":"Melanoma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"41.8","upperLimit":"81.2","value":"63.2"},{"groupId":"OG002","lowerLimit":"23.0","upperLimit":"63.2","value":"42.1"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"19"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"19"}],"units":"Participants"}],"title":"Renal cell cancer (RCC)"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"51.9","upperLimit":"78.0","value":"65.9"},{"groupId":"OG002","lowerLimit":"33.3","upperLimit":"77.3","value":"56.3"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"41"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"16"}],"units":"Participants"}],"title":"Mesothelioma"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"16.8","upperLimit":"53.6","value":"33.3"},{"groupId":"OG001","lowerLimit":"9.9","upperLimit":"43.7","value":"23.8"},{"groupId":"OG002","lowerLimit":"6.1","upperLimit":"46.6","value":"21.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"14"}],"units":"Participants"}],"title":"Triple negative breast cancer (TNBC)"}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"93"}],"units":"Participants"}],"description":"Tumor response was based on local investigator assessment and the assessment criteria was Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1). DCR per RECIST 1.1 is defined as the percentage of participants with a best overall response of Complete Response (CR), Partial Response (PR) or Stable Disease (SD).\n\nFor RECIST v1.1, CR=Disappearance of all non-nodal target lesions. In addition, any pathological lymph nodes assigned as target lesions must have a reduction in short axis to \\< 10 mm; PR= At least a 30% decrease in the sum of diameters of all target lesions, taking as reference the baseline sum of diameters; SD= Neither sufficient shrinkage to qualify for PR or CR nor an increase in lesions which would qualify for progression.\n\nDCR is reported by tumor type.","dispersionType":"90% Confidence Interval","groups":[{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients naïve to anti-PD-1/PD-L1","id":"OG000","title":"Phase 2: Naive - LAG525 400 mg Q3W + PDR001 300 mg Q3W"},{"description":"Combination LAG525 600 mg + PDR001 400 mg (Q4W/Q4W) in patients naïve to anti-PD-1/PD-L1","id":"OG001","title":"Phase 2: Naive - LAG525 600 mg Q4W + PDR001 400 mg Q4W"},{"description":"Combination LAG525 400 mg + PDR001 300 mg (Q3W/Q3W) in patients pre-treated with anti-PD-1/PD-L1","id":"OG002","title":"Phase 2: Pre-treated - LAG525 400 mg Q3W + PDR001 300 mg Q3W"}],"paramType":"NUMBER","populationDescription":"All patients in phase 2 who received at least one full or partial dose of LAG525 or PDR001.","reportingStatus":"POSTED","timeFrame":"From start of treatment until end of treatment, assessed up to 2.6 years","title":"Phase 2: Disease Control Rate (DCR) Per RECIST 1.1","type":"SECONDARY","unitOfMeasure":"percentage of participants"}